Theradiag: growth of nearly 10% in 2022
The company points out that its Theranostics business will again post solid growth in 2022 (+10.1%), despite fewer instruments sold, as will its historical in vitro diagnostics business (+9.2%), despite the closure of the Covid test business in 2021.
Driven by its new strategic plan, the company will continue to improve its performance indicators in the coming half-years", concludes Pierre Morgon, Chairman of Theradiag's Board of Directors.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction